Oxford–AstraZeneca

Oxford–AstraZeneca COVID-19 vaccine (also known as AZD1222, Vaxzevria, and Covishield) is a viral vector vaccine for prevention of COVID-19. Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1.

Development and production

The vaccine was developed by Oxford University's Oxford Vaccine Group and the Jenner Institute, in partnership with the pharmaceutical company AstraZeneca. The development process began in January 2020, following the sequencing of the SARS-CoV-2 virus.

Efficacy

Clinical trials have shown the Oxford–AstraZeneca vaccine to be effective at preventing COVID-19, significantly reducing hospitalisations and deaths from the disease. The vaccine has been shown to be effective against various COVID-19 variants.

Distribution

The vaccine has been widely distributed globally, with over a billion doses delivered as of September 2021. It is a key vaccine in the COVAX scheme, which aims to ensure equitable access to COVID-19 vaccines.

Side effects

Common side effects include pain and tenderness at the injection site, headache, fatigue, and flu-like symptoms. Rare but serious side effects include thrombosis with thrombocytopenia syndrome (TTS).

See also

• COVID-19 vaccine
• COVID-19 pandemic
• Vaccine nationalism

Oxford–AstraZeneca Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski